Biopharmaceuticals — from therapeutic proteins to vaccines — rely on recombinant expression systems. Yet one hidden challenge in production is the removal and quantification of host cell proteins (HCPs), which are…
In the in vitro diagnostics (IVD) world, a small leap in reagent quality can translate into significantly better test accuracy, lower costs, and higher trust. That leap increasingly depends on recombinant…
The Backbone of Reliable Diagnostics When clinical labs or diagnostic manufacturers deploy an assay, they trust that the reagents in #Batch A will behave the same as in #Batch B,…
In today’s fast-moving biopharma landscape, speed and reliability are non-negotiable. The ability to go from gene → expression → purification → functional protein is the foundation of drug discovery, diagnostics, and biologics…
Introduction When producing biotherapeutics—monoclonal antibodies, fusion proteins, or other recombinant products—the cells that make them matter almost as much as the product itself. In mammalian expression systems, CHO (Chinese Hamster Ovary) cells…
Introduction Diagnostics is the frontline of healthcare. The earlier and more accurately we detect disease markers, the faster patients can access treatment and the easier it becomes to control outbreaks.…
In diagnostics, trust is everything. A single unreliable reagent, inconsistent antibody pair, or delayed shipment can derail entire validation pipelines. For diagnostic manufacturers competing in a fast-moving global market, consistency…
In diagnostics, choosing the right antigen determines the difference between ambiguous results and clear, actionable insights. This is especially true for two critical markers: Native CRP (C-Reactive Protein) HBsAg Ad/Ay…
Detecting neutralizing anti-etanercept antibodies is essential for accurate anti-drug antibody (ADA) and cell-based assays. These antibodies can directly negate the biologic activity of etanercept, affecting efficacy, pharmacokinetics, safety, and clinical outcomes. In this article, we…
In the competitive world of diagnostics, every decision - from assay design to reagent selection, impacts product success. For diagnostic manufacturers, accuracy is non-negotiable. And at the heart of accuracy lies…
In diagnostic manufacturing, speed and cost pressures often tempt manufacturers to cut corners on antibody selection. However, using unvalidated antibody pairs, especially in Lateral Flow Assays (LFAs) for targets like Dengue NS1…
Importance of antibody pair validation in LFA development Rapid diagnostic tests, especially lateral flow immunoassays (LFIAs) are critical for early detection of viruses like Dengue NS1 and HBsAg, particularly in resource-limited settings. But…
